Table 3.
Patient characteristics at 2MT—UK
| Any use | LAMA | LABA | LAMA + LABA | ICS | LABA + ICS | LAMA + ICS | LAMA + LABA + ICS | ||
|---|---|---|---|---|---|---|---|---|---|
| Number of patients, N (%) | 2461 (100.0) | 222 (9.0) | 101 (4.1) | 970 (39.4) | 60 (2.4) | 338 (13.7) | 85 (3.5) | 685 (27.8) | |
| Age, mean (SD) | 67.6 (10.1) | 68.9 (10.4) | 70.1 (9.6) | 67.4 (9.7) | 67.1 (10.9) | 68.6 (11.1) | 65.5 (10.7) | 66.8 (10.0) | |
| Male gender, n (%) | 1375 (55.9) | 127 (57.2) | 51 (50.5) | 555 (57.2) | 31 (51.7) | 191 (56.5) | 37 (43.5) | 383 (55.9) | |
| FEV1/FVC, median (IQR) | 60.0 (50.0; 68.0) | 61.0 (51.0; 67.0) | 61.0 (49.2; 68.0) | 59.0 (49.0; 67.0) | 63.0 (53.5; 69.0) | 61.9 (51.0; 69.0) | 63.0 (55.0; 68.3) | 59.0 (49.0; 67.0) | |
| Exacerbations | |||||||||
| COPD exacerbations in previous year, n (%) | |||||||||
| 0 | 1351 (54.9) | 144 (64.9) | 63 (62.4) | 590 (60.8) | 34 (56.7) | 172 (50.9) | 49 (57.7) | 299 (43.7) | |
| 1 | 515 (20.9) | 44 (19.8) | 20 (19.8) | 200 (20.6) | 14 (2.3) | 76 (22.5) | 17 (20.0) | 144 (21.0) | |
| 2 | 271 (11.0) | 22 (9.9) | 9 (8.9) | 92 (9.5) | < 5 | 41 (12.1) | 9 (10.6) | 97 (14.2) | |
| 3 | 163 (6.6) | 7 (3.2) | 5 (5.0) | 53 (5.5) | < 5 | 23 (6.8) | < 5 | 67 (9.8) | |
| 4 | 80 (3.3) | < 5 | < 5 | 17 (1.8) | 6 (10.0) | 15 (4.4) | < 5 | 33 (4.8) | |
| 5+ | 81 (3.3) | < 5 | < 5 | 18 (1.9) | < 5 | 11 (3.3) | < 5 | 45 (6.6) | |
| Comorbidities and concomitant medication use | |||||||||
| Charlson–Deyo comorbidity score, mean (SD) | 2.4 (1.7) | 2.5 (1.9) | 2.5 (2.0) | 2.4 (1.7) | 2.8 (1.7) | 2.6 (1.8) | 2.0 (1.4) | 2.3 (1.6) | |
| Upper respiratory tract infection, n (%) | 1087 (44.2) | 107 (48.2) | 45 (44.6) | 407 (42.0) | 25 (41.7) | 153 (45.3) | 49 (57.7) | 301 (43.9) | |
| Lower respiratory tract infection, n (%) | 1398 (56.8) | 125 (56.3) | 67 (66.3) | 523 (53.9) | 36 (60.0) | 202 (59.8) | 47 (55.3) | 398 (58.1) | |
| Pneumonia, n (%) | 236 (9.6) | 23 (10.4) | 8 (7.9) | 82 (8.5) | 6 (10.0) | 35 (10.4) | 9 (10.6) | 73 (10.7) | |
| Chronic bronchitis, n (%) | 15 (0.6) | – | < 5 | 7 (0.7) | – | < 5 | < 5 | < 5 | |
| Lung fibrosis, n (%) | 27 (1.1) | < 5 | – | 12 (1.2) | < 5 | < 5 | – | 8 (1.2) | |
| Oral corticosteroids, n (%) | 1066 (43.3) | 71 (32.0) | 36 (35.6) | 356 (36.7) | 25 (41.7) | 152 (45.0) | 41 (48.2) | 385 (56.2) | |
| Oral antibiotics, n (%) | 1583 (64.3) | 130 (58.6) | 57 (56.4) | 575 (59.3) | 39 (65.0) | 233 (68.9) | 56 (65.9) | 493 (72.0) | |
| Oxygen therapy, n (%) | 17 (0.7) | – | – | 8 (0.8) | – | < 5 | < 5 | 5 (0.7) | |
| Time to treatment switch | |||||||||
| Days between 1MT and 2MT, mean (SD) | 297.1 (257.0) | 298.2 (255.3) | 283.1 (275.5) | 340.7 (268.1) | 316.0 (283.4) | 227.5 (209.2) | 205.2 (186.0) | 281.1 (253.8) | |
| Days between 1MT and 2MT, median (IQR) | 218.0 (86.0; 428.0) | 225.5 (96.0; 415.0) | 141.0 (74.0; 412.0) | 284.0 (113.0; 483.0) | 239.5 (61.5; 528.0) | 155.5 (67.0; 335.0) | 158.0 (71.0; 281.0) | 197.0 (82.0; 397.0) | |
1MT first maintenance therapy, 2MT second maintenance therapy, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, ICS inhaled corticosteroids, IQR interquartile range, LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist, NR not reported, SD standard deviation